Amarin | AMRN - Zahlungsmittel Und Äquivalente





Zahlungsmittel Und Äquivalente Veränderung Datum
AbbVie USD 9.39B 4.16B 2026-03
Alnylam Pharmaceuticals USD 1.71B 53.53M 2026-03
Amarin USD 131.06M 3.6M 2026-03
AstraZeneca USD 7.56B 1.85B 2026-03
BioCryst Pharmaceuticals USD 171.59M 164.32M 2026-03
DBV Technologies USD 194.17M 124.33M 2025-12
Esperion Therapeutics USD 156.16M 11.69M 2026-03
GlaxoSmithKline GBP 3.44B 292M 2026-03
Halozyme Therapeutics USD 309.75M 175.93M 2026-03
Heron Therapeutics USD 26.12M 2.53M 2026-03
Ionis Pharmaceuticals USD 1.92B 758M 2026-03
Nektar Therapeutics USD 15.12M 25.92M 2025-12
Neurocrine Biosciences USD 266.5M 446.5M 2026-03
Novartis USD 6.88B 4.56B 2026-03